IRIX (IRIDEX) Valuation Rank


IRIX IRIDEX Corp IRIX
66 GF Score
Price $1.19
GF Value $1.70
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is IRIDEX Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

IRIDEX Valuation Rank Related Terms

IRIX
66GF Score
IRIDEX Corp IRIX
Valuation Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is IRIDEX (IRIX) Overvalued in 2026?

Based on GuruFocus' analysis, IRIDEX stock appears to be undervalued. The current stock price of $1.19 is trading 30% below its estimated GF Value™ of $1.70. GuruFocus considers IRIDEX to be Possible Value Trap.

Key valuation signals for IRIX:

  • Valuation Rank:
  • GF Value™: $1.70 vs. price of $1.19 (30% below fair value)
  • GF Score™: 66/100 with 3 warning signs

No single metric tells the full story. See the IRIX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

IRIDEX Business Description

Address 1212 Terra Bella Avenue, Mountain View, CA, USA, 94043
IRIDEX Corp is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures used to treat sight-threatening eye conditions, including glaucoma and retinal diseases. Its products include Lasers, Laser delivery devices, Glaucoma devices, Retinal surgical instruments, and Veterinary and ENT products. The firm also powers its products with its proprietary Micropulse technology. The company operates in only one reportable segment, Ophthalmology. It derives revenues from the sale of consoles, delivery devices, consumables, services, and support activities. The geographical segments of the company include the United States, which drives maximum revenue, Europe, and the Americas, excluding the U.S. and Asia/Pacific Rim.
66GF Score

Get the complete analysis for IRIX

Valuation Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.19
Price
$1.70
GF Value